--- title: "Missed Blood Pressure Rechecks: The UK's Hypertension Follow-Up Gap" description: "Around 30% of people on a UK GP's hypertension register aren't managed to NICE's target, and recall keeps slipping in private and mixed-list practices." url: https://www.getarbol.com/en/blog/hypertension-follow-up-private-gp-uk/ lang: en --- # Missed Blood Pressure Rechecks: The UK's Hypertension Follow-Up Gap Around 30% of people on a UK GP's hypertension register aren't managed to NICE's target, and recall keeps slipping in private and mixed-list practices. [**Veronica Tobon** Medical Advisor, Clínica Sierra Vista](https://www.getarbol.com/en/blog/authors/veronica-tobon/) August 7, 2026 10 min read Around 30% of people on a UK GP’s hypertension register are not managed down to NICE’s target blood pressure, and blood-pressure recording is still roughly ten percentage points below its pre-pandemic level, according to [NHS England’s own cardiovascular audit data](https://www.england.nhs.uk/ourwork/prevention/cardiovascular-disease/). The guideline assumes an active recall: measure, treat, recheck, repeat. What actually breaks that cycle, in a private or mixed-list practice without a dedicated recall team, is rarely the clinical decision — it’s the step where somebody has to pick up the phone and get the patient back in the room. ## The scale of the gap, in the NHS’s own figures Hypertension is not a rare-disease problem in England. The [British Heart Foundation](https://www.bhf.org.uk/informationsupport/risk-factors/high-blood-pressure) puts the number of UK adults with undiagnosed high blood pressure at around 5 million — people who have never had the reading that would put them on a register in the first place. Among those who are diagnosed and already on a practice’s hypertension register, NHS England’s own reporting states that 30% are not managed optimally against the target set out in [NICE guideline NG136](https://www.nice.org.uk/guidance/ng136). And the mechanism that is supposed to catch both groups — routine blood-pressure recording during any GP contact — has not recovered from the disruption of the pandemic years: NHS England cites CVDPREVENT audit data showing recording rates still around 10 percentage points below the pre-pandemic baseline, with the lowest active-monitoring rates concentrated among Black and mixed-ethnicity patient groups. Hypertension follow-up in England, by the numbers Three ways the same gap shows up \~5 million UK adults with undiagnosed high blood pressure British Heart Foundation 30% of registered hypertensive patients not managed to target BP NHS England \~10 pp blood-pressure recording still below the pre-pandemic baseline NHS England / CVDPREVENT Fuente: British Heart Foundation; NHS England None of these numbers describe a shortage of guidance. NICE’s NG136 is explicit: adults under 80 are treated to a clinic reading below 140/90 mmHg (135/85 mmHg on home or ambulatory monitoring), and everyone with diagnosed hypertension gets what the guideline calls, in recommendation 1.4.24, “an annual review of care… to monitor blood pressure, provide people with support, and discuss their lifestyle, symptoms and medication.” Even people who have not yet crossed the threshold for a diagnosis aren’t left unmeasured on paper: NG136 asks practices to recheck clinic blood pressure at least every five years in adults with a raised-but-undiagnosed reading, and at least annually in anyone with type 2 diabetes who hasn’t already been diagnosed with hypertension. What’s missing is not the standard. It’s the mechanism that reliably gets each person back through the door on schedule, year after year, without depending on them to remember and ring in themselves. Hypertension earns this level of guideline detail because the downside of a missed recheck isn’t abstract. Left uncontrolled, raised blood pressure is one of the largest single contributors to stroke, heart attack, heart failure and chronic kidney disease in the UK — which is exactly why NICE frames the annual review as a floor, not an aspiration, and why NHS England tracks the recording gap as a patient-safety indicator rather than a housekeeping metric. A patient who is quietly overdue isn’t waiting in a queue for something optional; they’re carrying an unmanaged cardiovascular risk that the system has already identified and, on paper, already has a plan for. ## What “falling off the register” looks like in practice Where the register actually sits Share of registered hypertensive patients not controlled to NICE's target not at target BP: 30% Fuente: NHS England, Cardiovascular disease high impact interventions A hypertension register is not a static list. People move onto it after a diagnosis and are meant to move through it on a fixed annual rhythm for the rest of their lives — a rhythm that assumes the practice, not the patient, drives the next appointment. When that outbound step lapses, the person doesn’t disappear from the register; they simply stop being reviewed on time, which is functionally the same as not being on it at all for the months or years the gap runs. [Public Health England’s own analysis, still published on GOV.UK](https://www.gov.uk/government/publications/health-matters-combating-high-blood-pressure/health-matters-combating-high-blood-pressure), found that practices had no blood-pressure reading on file for around 10% of patients aged 45 and over across a five-year window — not a missed annual review, a complete absence of any reading at all. The same report set England’s diagnosed-and-managed-to-target rate at 35%, against 65% in Canada on a comparable measure — the kind of gap that isn’t explained by clinical difficulty, because the underlying medicine (measure, treat, titrate, recheck) is the same drug and the same guideline threshold in both countries. What differs is whether someone in the system is actively responsible for making sure the recheck happens. ## Why private and mixed-list practices carry more of this risk, not less NHS-contracted general practice at least has a structural nudge built in: the Quality and Outcomes Framework ties a portion of practice income to maintaining an accurate hypertension register and completing annual reviews, and the Care Quality Commission inspects against exactly this kind of chronic-disease follow-up. That incentive doesn’t close the gap on its own — the 30% and the ten-point shortfall above are measured on QOF-registered NHS patients — but it does mean a recall process, however imperfect, usually exists somewhere in the practice’s workflow. A private or self-pay GP practice, or the private-patient list inside a mixed practice, sits outside that framework almost entirely. There is no QOF payment attached to whether a self-pay hypertensive patient gets called back in twelve months, and no external inspection specifically checking that they were. Recall becomes something the practice does because it chooses to build the process, not because a funding formula requires it — which means it depends entirely on whether someone on the admin team has the time, on a given week, to run down a spreadsheet of overdue patients and start making calls. Add a receptionist covering reception, billing and correspondence at once, and a hypertension recall list is exactly the kind of task that gets pushed to “next week” until the next annual review is, in effect, whenever the patient happens to book something else. The clinical stakes don’t change because the funding model does. A private-pay patient whose blood pressure quietly drifts above target for eighteen months carries the same stroke and cardiovascular risk as an NHS-list patient in the same position — the difference is only in who, if anyone, is watching the calendar. There’s also a practical asymmetry in how each type of patient tends to respond to being chased. A patient on an NHS list has usually experienced the practice’s standard recall letter or text before and may simply defer, assuming the practice will follow up again if it’s genuinely overdue — the annual review is a familiar rhythm, even where it slips. A self-pay patient, by contrast, has often chosen the practice specifically for a more personal, responsive standard of care; a missed recall reads less like routine NHS administration and more like an unmet expectation. That makes the follow-up gap not just a clinical risk but a retention one — the kind of quiet drift that shows up later as a patient who simply doesn’t renew, rather than one who complains. ## How Arbol closes the gap without adding headcount This is a contact problem before it is a clinical one. The practice already knows who is overdue — the register says so — and the guideline already says what needs to happen next. What’s missing is the reliable, repeated act of reaching each person, at the right interval, without it depending on spare staff capacity that a busy week doesn’t have. Arbol works from a practice’s own recall list and closes that specific gap. It automatically flags every patient who has passed their due date for a hypertension review, reaches out by phone call, text message or WhatsApp — whichever channel that patient is most likely to actually respond to — and handles the booking conversation itself: offering the next available slot, confirming attendance, or rescheduling on the spot if the first time doesn’t suit. Every outcome is logged back against the patient’s record, so the practice always has an accurate, current picture of who has been contacted, who has booked, and who still needs a second attempt — rather than a spreadsheet nobody has opened since the last audit. 1. 1 Flag who is overdue Arbol cross-references the practice's hypertension register against each patient's last review date, so nobody depends on someone remembering to check. 2. 2 Reach out automatically Outbound calls, SMS or WhatsApp messages go out on a set schedule, in the channel each patient is most likely to answer. 3. 3 Confirm or rebook in the same conversation The patient can book, confirm or reschedule their review without waiting for reception to call back. 4. 4 Log the outcome Every contact and its result is recorded against the patient, so the practice can see exactly who is still outstanding at any point. None of this replaces clinical judgement — what happens inside the review room is still entirely down to the GP and the guideline. What Arbol changes is whether the person gets back into that room on schedule in the first place, at any hour, without the practice having to carve out staff time it doesn’t reliably have. For a self-pay or mixed practice with no QOF payment riding on the outcome, that’s often the only thing standing between a well-run hypertension programme and a register that quietly goes stale. ## What your practice can do this week Before you change anything, see the size of your own gap - Pull the hypertension register and flag everyone whose last blood-pressure reading is more than 12 months old This is the practical equivalent of NICE NG136's annual review requirement — measured against your own list, not a national average. - Check how many of those overdue patients are self-pay or on a private list rather than NHS-contracted This is usually the group with no QOF payment attached to their recall, and often the least formal follow-up process. - Ask who currently owns the recall call list, by name "Reception, when they have time" is not an owner — it's how a register goes quiet. - Look at how many recall attempts get a response on the first try versus how many need a second or third contact This is the number that tells you whether the bottleneck is finding time to call, or finding time to call back. If your practice runs a mixed NHS and private list, the incentive gap above is worth reading alongside how it plays out in comparable general practice models — see [Arbol’s look at GMS versus private GP visits in Ireland](https://www.getarbol.com/en/blog/gms-vs-private-gp-ireland/) for how a parallel funding split shapes follow-up elsewhere, and [how after-hours contact gaps compound the same problem in general practice](https://www.getarbol.com/en/blog/after-hours-coverage-general-practice-nz/). For a broader view of how proactive, always-on patient contact works across different practice types, see [Arbol’s homepage](https://www.getarbol.com/en/). Disclaimer This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition. ## More to read - Cardiology Jul 27, 2026 ### [What a Post-Discharge Hypertension Follow-Up Call Should Cover](https://www.getarbol.com/en/blog/post-discharge-hypertension-followup-us/) Only 22.5% of US adults with hypertension have their blood pressure controlled. Here's the first-week follow-up protocol that actually lowers readmission risk. 8 min read Samuel Giraldo - Cardiology Jul 26, 2026 ### [Heart failure follow-up calls: a protocol for Australian GPs](https://www.getarbol.com/en/blog/heart-failure-followup-gp-australia/) Australian guidance points to GP review within about a week of a heart failure discharge. Here is how a GP clinic can structure that follow-up call safely. 9 min read David Lara - Pediatrics Aug 6, 2026 ### [The UK's Vaccine Catch-Up Gap Is a Recall Problem, Not Refusal](https://www.getarbol.com/en/blog/childhood-immunisation-catchup-uk/) UKHSA data shows MMR coverage in England still below target as measles cases rise, and the gap sits mostly in missed GP recall for catch-up doses, not refusal. 9 min read Emilia Santander ## Every call answered. Every appointment in its place. Arbol answers calls and WhatsApp 24/7, and books and confirms appointments on top of the medical record and systems you already use. [Book a demo](https://cal.com/tomas-giraldo-pdfbl9/30-min-arbol-ai-demo) --- **Arbol AI** — AI agents for clinics and healthcare providers: they answer and reach patients by phone, WhatsApp, SMS, email and web chat, book their appointments 24/7 and keep a record of every conversation. - Original page: - Book a demo: · Pricing: - Agent index: · Support: